ACON stock icon



About: Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The Company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.

Employees: 6

Funds holding %
of 6,702 funds
Analysts bullish %
News positive %
of 3 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

2.78% less ownership

Funds ownership: 6.6% [Q4 2023] → 3.81% (-2.78%) [Q1 2024]

22% less funds holding

Funds holding: 9 [Q4 2023] → 7 (-2) [Q1 2024]

28% less capital invested

Capital invested by funds: $124K [Q4 2023] → $89.4K (-$34.6K) [Q1 2024]

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

Research analyst outlook

We haven’t received any recent analyst ratings for ACON.

Financial journalist opinion

Based on 3 articles about ACON published over the past 30 days